Moreover, Akt activation was recently defined as a convergent feature of acquired EGFR TKI resistance, and increased p-Akt levels were observed in clinical specimens obtained from EGFR-mutant NSCLC patients who acquired EGFR TKI resistance [49, 50]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.